Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 20, 2026American Journal of Respiratory and Critical Care Medicine

B32-37 Safety and Efficacy of Omalizumab in Severe Asthma Patients With Elevated IgE Levels: A Two-year Retrospective Review From Mumbai

View Full Paper
Ask AI
Bookmark
Share

Authors

JNJ P NairLokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical CollegeSTS M ThorveLokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical CollegeSWS R WaghmareLokmanya Tilak Municipal General Hospital and Lokmanya Tilak Municipal Medical College

Discussion

Loading...

Member takes

Implication

Retrospective review finds Omalizumab improves symptoms and lung function in severe asthma patients with high IgE levels.

Key Points

  • To evaluate the safety and efficacy of Omalizumab in severe asthma patients with elevated serum IgE levels.
  • Retrospective review of severe asthma patients uncontrolled on high-dose inhaled therapy conducted between 2023 and 2025.
  • Patients with serum IgE >1500 IU/mL received Omalizumab 300 mg subcutaneously every month for six months.
  • Post-treatment assessments included dyspnea scores, Asthma Control Questionnaire results, spirometry, and serum IgE levels.
  • Mean FEV₁ improved from 0.83 L to 1.04 L (mean change: 210 mL, p = 0.005).
  • Mean serum IgE levels reduced from 5701 IU/mL to 4127 IU/mL (mean change: 1574 IU/mL, p = 0.022).
  • No adverse reactions were reported.

Cite This Study

Nair et al. (2026) studied this question.

synapsesocial.com/papers/6a0d4f92f03e14405aa9ae7ehttps://doi.org/10.1093/ajrccm/aamag162.477
View Full Paper
Ask AI
Bookmark
Share